Clinical Trial Update: Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2) [Phase 1]

View source ↗

Summary

A Phase I dose-escalation trial of BAY1187982 in FGFR2-expressing advanced solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• BAY1187982 (BAY1187982)

Snippet

Sponsor: Bayer | Conditions: Medical Oncology | Phase 1 | Status: TERMINATED